FTC approves final settlement on generic drug divestiture

The Federal Trade Commission gave final approval to a settlement that satisfies its concerns that Impax Laboratories Inc.’s purchase of CorePharma would be anticompetitive. Under the agreement the companies will sell CorePharma’s rights and assets to generic pilocarpine tablets, which are used to treat dry mouth, and generic ursodiol tablets,